Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors

This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

Pancreatic Ductal AdenocarcinomaNon Small Cell Lung CancerColorectal Cancer+2 more

Verastem, Inc.NCT07020221